Good and bad news about dementia abounds this week, as MDLinx covers the incredible worldwide reductions in the disease (good news) that disproportionately benefit certain people (bad news), as well as risk factors for the disease we can all control (good news) and some we can’t (there’s that bad news again). Beyond dementia, we highlight…
This week we’ve got lots of good news (and a little bad) about Alzheimer’s disease—from incredible advancements in assessing risk factors (up to 50 years before onset) to the potential for a faster, cheaper, more accessible diagnosis, and even new ways a leukemia drug might make a big difference for patients suffering from the all-too-common…
This week, we’re zooming in on new strategies neurologists can use to help patients during the COVID-19 pandemic, as well as a few old strategies that might not make much sense in this strange new world. Don’t worry though, we’re experiencing a bit of pandemic fatigue, too—that’s why we’re also bringing you some hopeful news…
This week, we bring you some good news about new biomarkers, therapies, and patient management strategies that are poised to ease the burden of neurological disorders like Alzheimer’s disease—the cost of which might be higher than you think. (Want to know exactly how much? Skip ahead to the Trivia section.) This week’s issue of the…
Although the coronavirus has put the brakes on a number of clinical trials and life-changing drug launches, it still hasn’t stopped neuroscientists from gaining new understandings of the brain and its many disorders. For example, could a certain cocktail prevent Alzheimer disease? Could a common asthma drug help treat a notorious neurodegenerative disease? And could…
